Living Medical Textbook - Oncology - Projects In Knowledge - Tumor Immunology and Immunotherapy: Metastatic Melanoma Edition Table of Contents - Autoimmune Effects of CTLA-4 Antibodies: Management and Correlation with Benefit CME Information

This CME activity has reached its termination date and no longer offers continuing education credit. Please note that expired CME activities may not contain the most up-to-date information available.

Click here to view our current activities in Oncology.
ACCME Disclaimer

Chapter 5 – Autoimmune Effects of CTLA-4 Antibodies: Management and Correlation with Benefit

Editor-In-Chief
	Jeffrey S. Weber, MD, PhD Senior Member, Moffitt Cancer Center Director, Comprehensive Melanoma Research Center Professor, Department of Oncologic Sciences H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
top

Activity Goal
The goal of this CME activity is to examine the role of the immune system in fighting cancer and potential strategies for re-educating the immune system to break tolerance of "self" antigens that mask tumors from cellular immunity.

Target Audience
This activity is designed for medical oncologists, dermatologists, and other clinicians who interact with patients with melanoma or other solid tumors.

Learning Objective

Prepare strategies to manage side effects of CTLA-4 antibodies in patients with melanoma in order to reduce their impact on patient quality of life while maintaining therapeutic dosing.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge^® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).

Jeffrey S. Weber, MD, PhD, has mutual patent ownership of ipilimumab with Bristol-Myers Squibb and Medarex, Inc.

Lauren A. Cerruto has no significant relationships to disclose.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top

1843.05